Tagged With "white blood cells"
Blog Post
2016 Spring Allergy Capitals Report Ranks The Most Challenging Cities Nationwide For Allergies
Today, the Asthma and Allergy Foundation of America (AAFA), a leading patient advocacy organization in the United States representing nearly 61 million Americans who experience asthma or allergies, released its annual Spring Allergy Capitals™ report. The report identifies the 100 most challenging places to live with spring allergies in the U.S. Jackson, MS is the most challenging U.S. city to live for the second year in a row based on higher than average pollen scores, higher than average...
Blog Post
AAFA Explains: Allergy Shots—Fighting the Cause of Allergies
If you are one of the 50 million Americans living with allergies, you’re probably familiar with the tell-tale signs of allergies, such as sneezing, itchy nose, and watery eyes. But do you know what causes these symptoms? Let’s start at the beginning. An allergy is a disease of the immune system. The body’s immune system receives input from the environment and produces a response. Its purpose is to recognize and attack foreign invaders, such as bacteria and parasites. An allergy occurs when...
Blog Post
AAFA Study Highlights Negative Impact Eczema Can Have on Quality of Life
If you’ve never suffered from eczema, also known as atopic dermatitis, you probably aren’t aware of the negative impact it can have on quality of life. The severe itching, redness and excessively dry skin all make life miserable for those who suffer from the allergic disease.
Blog Post
AAFA Urges Inclusion of Patient Voice in Analysis of Costly New Asthma Drugs
Biologics are a new class of drugs that fight disease at the source . Instead of attacking symptoms, these drugs target diseases like asthma at a molecular level. These newer types of drugs are more expensive than older medicines. That is prompting public discussion on how to pay for them. The cost of caring for patients with the most severe forms of asthma represents a majority of asthma healthcare spending. In addition, asthma is a leading cause of missed time from work and school. Last...
Blog Post
Asthma and Allergy Research Review, April-June 2017
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Blog Post
Breathing in the Boat: It Was All Worth It
On Oct. 14, 2017, I began my travel across the world to compete at the 13th International Dragon Boat Federation’s Nations World Championships on Dianchi Lake in Kunming, China, after a long and unlikely journey to overcome asthma symptoms that nearly prevented me from competing at all.
Blog Post
Hives That Won’t Go Away: The Basics of CIU
Hives, those annoying itchy red bumps, often occur with an allergic reaction or sometimes a viral infection. Or sometimes, they can be more serious when they happen with a severe allergic reaction called anaphylaxis.
Blog Post
Does Growing up on Amish Farms Protect Children Against Asthma?
Can the house dust of a rural farming community hold clues to protecting people from developing asthma ? Researchers from several universities studied 60 children ages 7-14 from two similar, but slightly different, farming communities. Thirty were Amish children. Thirty were Hutterite. These groups are similar in that they share a common ancestry and have remained relatively isolated in their communities after immigration to the United States. They share other factors known to have...
Blog Post Featured
Dr. Philip Norman: An AAFA Tribute to an Allergy Legend
If you’ve ever benefited from immunotherapy (allergy shots, SLIT or oral immunotherapy), you can thank Dr. Philip Sidney Norman. Dr. Norman put allergy research on the map. He is known as the “father of modern immunotherapy for allergic disease” and even coined the term “allergen immunotherapy.” As an allergist and researcher for more than 50 years, he published 237 research papers and more than 100 book chapters and reviews. And for many decades, he was an important part of AAFA.
Blog Post
Dupilumab Shows Benefit for Those With Severe Asthma During Clinical Trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints.
Blog Post
FDA Approves a New Treatment Option for Those With Severe Asthma
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Blog Post
FDA Approves Cinqair to Treat Severe Asthma
FDA News Release FDA approves Cinqair to treat severe asthma For Immediate Release March 23, 2016 Inquiries Media Andrea Fischer 301-796-0393 Consumers 888-INFO-FDA Release The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current...
Blog Post
FDA Approves Dupixent® for Treatment of Asthma
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype
and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post
FDA Approves FASENRA® Pre-Filled Auto-Injector Pen for Self-Administration
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).
Blog Post
FDA Approves First Generic ADVAIR DISKUS® for Asthma Treatment
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Blog Post Featured
FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.
Blog Post
FDA Approves Generic of Proventil HFA Albuterol Inhaler to Meet Demand Due to COVID-19
The U.S. Food and Drug Administration today approved the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Blog Post
FDA Approves ProAir HFA Generic, a Quick-Relief Medicine for Asthma
The U.S. Food and Drug Administration today approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.
Blog Post
FDA Approves Two New Asthma Inhalers
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Blog Post
FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Blog Post
FDA Will Consider Xolair for the Treatment of Nasal Polyps
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Blog Post
Food Allergies – Not Only a Childhood Disease
Researchers estimate the number of people with food allergies in the U.S. to be 32 million. It breaks down to 6 million children and 26 million adults – more than previously thought. 1 It is common for food allergies to develop in childhood, but you can develop a food allergy at any age. Adults are more likely to develop allergies to crustacean shellfish (like crabs, lobster or shrimp), peanuts, milk, tree nuts and fin fish. 1 Adult-onset food allergies are generally life-long and are not...
Blog Post
GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post
Global Initiative for Asthma (GINA) Recommends the Use of Fractional Exhaled Nitric Oxide (FeNO) Monitoring for Difficult-to-Treat and Severe Asthma Management
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
Blog Post Featured
Help Shape the Future of Asthma Treatment
Share your thoughts on the future of asthma treatment. Take two short surveys by Jan. 12, 2020, 11:59 p.m. ET, and we'll submit your responses to be considered for updates to the Guidelines for the Diagnosis and Management of Asthma.
Blog Post
Poverty Widens Gap in Care for Asthma and Allergies
Press Release Contact: Melissa Graham mgraham@aaaai.org (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
Blog Post
Preparing for Natural Disasters When You Have Asthma
If you have asthma, natural disasters could affect your health in unexpected ways. Chronic medical conditions like asthma can become worse when wildfires, tornadoes, severe flooding or earthquakes occur. Asthma flare-ups during a disaster can happen because of: Allergens in the air (pollen, mold, etc.) Irritants in the air (dust, smoke) Losing access to your treatments due to evacuation Strong emotions (fear, anxiety) Now is a good time to create a disaster planning kit with your asthma in...
Blog Post
Study Shows a Difference Between the Effects of Controlled Burns vs. Wildfires
Controlled burns are often used to help reduce and contain wildfires, but it turns out which burn is occurring can actually have an effect on your health, according to research presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Blog Post
Study Shows Mepolizumab to Be a Safe and Effective Long-Term Treatment Option for Severe Asthma
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control New study showed one third of patients had no exacerbations on long-term treatment with Nucala GlaxoSmithKline plc (GSK) today presented new data from the longest study of an anti-IL5 biologic treatment in severe...
Blog Post
Study Shows Red Meat Allergy May Come From Tick Saliva
Alpha-gal syndrome (AGS), a food allergy commonly known as red meat allergy, may develop from ticks’ saliva itself, whether a tick has fed on another animal before biting a human or not. This news comes from a study presented for the first time at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology.
Blog Post
Teva Announces FDA Approval of ProAir® Digihaler™
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. Learn more.
Blog Post
Teva Launches AirDuo™ RespiClick® and its Authorized Generic
[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...
Blog Post
Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication
QVAR® RediHaler™ (beclomethasone dipropionate HFA) Inhalation Aerosol is now available to patients by prescription! It is the first and only breath-actuated inhaled corticosteroid for the maintenance treatment of asthma in patients ages 4 and older. QVAR® RediHaler™ is not used to relieve sudden breathing problems and won’t replace a rescue inhaler.
Blog Post
Understanding Asthma Research: Informed Consent
Some people are hesitant to participate in research. This may be because of fear of the unknown or from past stories. But today, patients have rights to protect them during research studies. Before you join a study, you will asked to sign an informed consent document.
Blog Post
Understanding Asthma Research: The National Institutes of Health
When you hear about medical research, you probably hear about an organization called the NIH. The NIH is the United States’ medical research agency. It is also one of the top medical research agencies in the world.
Blog Post
FDA Warns About Potential Allergic Reactions With the Skin Antiseptic Chlorhexidine Gluconate
The U.S. Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. Although rare, the number of reports of serious allergic reactions to these products has increased over the last several years.
Blog Post
What If You’re Allergic to Grass? 10 Steps to Managing Grass Pollen Allergy
Grasses are one of the most common causes of allergy. Each year, plants (including grasses) release tiny pollen grains to fertilize other plants of the same species. Unfortunately for people with grass allergies, this pollen triggers allergic reactions.
Blog Post
Immunotherapy May Help People With Allergic Asthma Breathe Easier
Out of the 25 million people who have asthma, about 60% of them have allergic asthma. If you have allergic asthma, this means allergens trigger asthma symptoms. Immunotherapy may help allergic asthma symptoms.
Blog Post
Increasing Inhaled Steroids Temporarily Does Not Stop Asthma Flare-Ups in Children
Researchers have found that temporarily increasing the dosage of inhaled steroids when asthma symptoms begin to worsen does not effectively prevent severe flare-ups, and may be associated with slowing a child’s growth, challenging a common medical practice involving children with mild-to-moderate asthma.
Blog Post
Infant Gut Bacteria Affects Allergy and Asthma Risk
The microbial communities, or microbiota, that naturally colonize the digestive tract in very young infants can affect their risk of later developing childhood allergies and asthma.
Blog Post
Living With Asthma in Birmingham, Alabama, the #8 Asthma Capital
For many, asthma is caused by an allergic reaction to something. This is called allergic asthma is the most common. But a small number of people with asthma have “non-allergic asthma.” Lynn Johnson is part of this group. Lynn developed non-allergic asthma seven years ago, as an adult.
Blog Post
LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Blog Post
Asthma Medication Recall Alert: Montelukast Tablets From Camber Pharmaceuticals for Incorrect Drug in Bottle
The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.
Blog Post
Mylan Launches Authorized Generic for EpiPen® (epinephrine injection, USP) Auto-Injector
[Press Release] Mylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic Authorized Generic Offered at More Than 50% Below Wholesale Acquisition Cost of EpiPen Auto-Injector HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 / PRNewswire / -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the launch of the authorized generic for EpiPen ® (epinephrine injection, USP) Auto-Injector at a wholesale acquisition cost (WAC) of $300 per...
Blog Post
Teva Pharmaceuticals Prepares for Upcoming Launch of Daily Maintenance Asthma Medication
QVAR® RediHaler™ (beclomethasone dipropionate HFA) Inhalation Aerosol will become available by prescription on February 12, 2018. QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol will no longer be available to patients.
Comment
Re: Share Your Stories About Animals on Planes and How They Affect People With Asthma and Allergies
I agree masks just do not work to stop dander allergy. Mine is skin as well-- I break out in hives, eyes itching, and those reactions cause eosinophils (inflammatory blood cells produced in response to allergen exposure) which cause my entire allergic disease to flare up and causes vasculitis (blood vessel inflammation) and can damage organs (eosinophils surrounded my heart and caused a heart attack at age 28). My disease is one of many allergic diseases involving eosinophils and allergy,...
Comment
Re: Should You Have Pets If You Have a Pet Allergy?
No. You shouldn't. It is basically abuse to the allergic person. I have been the allergic person and it got so bad that after chronic exposure even doing all the strategies above and with antihistamines I developed asthma symtoms and shortly after went to the hospital because I thought I was having an asthma atrack turns out it was a heart attack caused by allergic blood cells called eosinophils surrounding my heart and choking it. I was diagnosed with a severe chronic allergic disease. My...
Comment
Re: Xolair Approved for Children with Asthma Triggered by Allergens
Jade just started her first round of Xolair Injections this past week. She's SO brave! But...I have to admit...It was a bittersweet moment; watching her sit there, calm, asking the nurse to count slowly for her, watching the needle, as she was given both injections. Outside of respectfully saying that it "kind of hurt, a lot", she didn't complain, or cry, or move, or refuse, or scream...she just sat still and watched! As a mom, this was a like a dream come true...at first. [{Sidebar} At this...
Comment
Re: AAFA Explains: Can Vitamin D Help My Asthma?
Could Vitamin D blood levels stem from absorption issues? Or a lack of sun on our skin, aka. outdoor time? Simply adding an isolate to treat symptoms gets us no closer to a remedy of the cause. Dig deep, many times it is less what we add to our bodies and more of what we subtract that brings our systems into homeostasis. #subtractionarymedicine
